Written answers
Wednesday, 15 February 2012
Department of Health
Drugs Payment Scheme
9:00 pm
Liam Twomey (Wexford, Fine Gael)
Link to this: Individually | In context
Question 270: To ask the Minister for Health the reason Pradaxa was removed from the drug allowance scheme; and if he will make a statement on the matter. [8683/12]
Róisín Shortall (Dublin North West, Labour)
Link to this: Individually | In context
Pradaxa is available under the GMS Scheme, the Drug Payment Scheme and other community drugs schemes for the prevention of blood clots in adult patients who have undergone elective hip replacement surgery or elective knee replacement surgery.
The HSE is assessing the availability of resources to provide for the long term treatment with Pradaxa for the prevention of stroke in patients with atrial fibrillation. This is a complicated process with long term implications. The HSE wrote to all GMS doctors and community pharmacy contractors in November 2011 to clarify the position in relation to Pradaxa. The HSE will continue to update health care professionals in relation to the matter.
The HSE does not intend to disturb established therapeutic regimens for patients whose treatment with Pradaxa for the prevention of stroke was initiated prior to the clarification.
No comments